New-onset atrial fibrillation - ED pathway
Acute AF management · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
New atrial fibrillation in the ED: stabilise, hunt for a precipitant, then choose rate or rhythm control and decide on anticoagulation. Haemodynamic instability mandates immediate cardioversion.
Assessment
Investigations
- ECG; assess haemodynamic stability and onset time (<48 h?)
- Identify precipitants: sepsis, PE, thyrotoxicosis, electrolytes, alcohol, ischaemia
- Bloods including TFTs, electrolytes; CHA2DS2-VASc and bleeding risk
Management
- Unstable (shock, ischaemia, syncope, heart failure): synchronised DC cardioversion
- Treat any precipitant (often the AF then settles)
- Rate control first-line for most: beta-blocker or diltiazem (digoxin if heart failure/hypotension)
- Rhythm control (flecainide if no structural heart disease, or amiodarone) if <48 h onset or anticoagulated/TOE-guided
- Anticoagulate based on CHA2DS2-VASc (and assess bleeding risk) - do not cardiovert >48 h or unknown onset without anticoagulation/TOE
- Admit or discharge with cardiology/arrhythmia follow-up per response
- Avoid AV-nodal blockers in pre-excited AF (WPW)
Drugs & doses
Beta-blocker or diltiazem (rate control)
Flecainide / amiodarone (rhythm control)
DC cardioversion (if unstable)
Anticoagulation per CHA2DS2-VASc
Disposition
Per response; cardiology follow-up.
Cardiovert unstable AF immediately, but for stable AF treat the precipitant, rate-control, and never cardiovert AF >48 h without anticoagulation or a TOE.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.